Can Pfizer Stock Get Back To Where It Was

For questions about this article or underlying research, email [email protected].

Pfizer Inc. (PFE) stock currently trades at roughly half the high it closed at in December 2021. Many shareholders still measure the shares against that close, treating the years since as a mere detour. If that old close is the target, how big a gain would Pfizer stock need to reach it?

Pfizer Stock Needs A 104% Gain To Get Back

Pfizer stock sits 51% below its old high, meaning a return to that peak would require a 104% gain from today's price. Even if the climb took three years, it would require an average annual return of 26.8%.

Has Pfizer Stock Ever Gained 104% In Three Years?

The shares have never achieved that gain over any full three-year period. Counting every possible stretch of 756 trading sessions that began and ended in the last ten years, one starting on each trading day, Pfizer stock never ended a window 104% higher than it started.

Pfizer's business may still perform well from here, and management raised its revenue forecast for 2026 in August. Pfizer stock did more than double from March 2020 to its December 2021 high. But it gave back enough that no full three-year stretch in the last decade ended 104% higher than it started. Returning to the high on that schedule would therefore mark a first for the shares in that time.

What Has Waiting Cost Pfizer Holders?

Anyone holding Pfizer since the high has now waited 4.9 years. The stock fell 51% before dividends over that span, or about 37% with dividends counted, while the S&P 500 rose 63.3% before dividends and about 75% with them. A holder who waited therefore took a loss on Pfizer's decline and also missed the broader market's advance.

Is Pfizer The Same Business It Was Then?

Pfizer today generates lower sales, and retains slightly less of each sale as operating profit, than it did in the twelve months before the stock peaked. Net income fell much further, partly because of $4.3 billion of non-cash impairments in the June 2026 quarter.

Nearly all of Pfizer's sales still come from its Biopharma segment, which includes medicines such as Eliquis, Padcev and Lorbrena. Overall revenue is down 7.5% from the twelve months before the high, and the operating margin has slipped from 28.5% to 26.7%.

The old high was therefore set by a larger, more profitable business than the one shareholders own today. The question for a Pfizer holder now is not when the stock will revisit its peak, but whether today's business is worth the 2.7 times yearly sales at which the shares currently trade.

How To Act On PFE?

Not necessarily on Pfizer alone, if your goal is long-term wealth. Wealth is built by owning the companies that keep outperforming, the leaders of their industries, wherever they are. Here is one company from Pfizer's own industry that has beaten it. Over the five years to October 2026, Viatris stock rose 59%, while Pfizer stock fell 9.3%.

Finding companies like these takes comparison across industries and sectors, and that is what the Trefis High Quality (HQ) Portfolio does. It holds 30 quality companies in equal weight and, since its inception in September 2020, has returned more than 105%, ahead of a benchmark that combines the S&P 500, S&P Mid-cap and Russell 2000. See how we find the leaders.

Spot an error or want more like this? Tell us in 10 seconds.